glp 1 insulin combo Practice Nursing - GLP-1 receptor agonists and their role in managing type 2 diabetes GLP-1 Agonists: A Comprehensive Overview

A 2023 study found a 20% cardiovascular risk reduction for obese individuals taking semaglutide compared to those not taking a GLP-1 drug

Saturated fat and cholesterol stay high

Wegovys monthly list price in the US is $1350

Full reimbursement is likely to be unaffordable for most publicly funded healthcare systems in the short term, but a steady reduction in the threshold for reimbursement is believed to be inevitable in the medium to long term

The Journal of the American Medical Association recently published diet and exercise guidance for people taking GLP-1s (3): Source: Mehrtash F, Dushay J, Manson JE

For instance, semaglutide received FDA and EMA approval for cardiovascular risk reduction in patients with obesity in 2024, and Novo Nordisk are also targeting the use of semaglutide in patients with obesity-related heart failure and metabolic associated steatohepatitis (MASH, formerly known as fatty liver disease)